NCT05895201 2024-04-29High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHDIndiana UniversityPhase 1/2 Withdrawn
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT00437086 2014-10-17Bortezomib in Treating Patients With Advanced Myeloproliferative DisordersMayo ClinicPhase EARLY_PHASE1 Completed30 enrolled
NCT00237627 2012-05-18Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast CancerUNC Lineberger Comprehensive Cancer CenterPhase 1/2 Completed107 enrolled